

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Jul 2026

Effect of allopurinol in preventing contrast induced nephropathy among patients undergoing elective PCI

Protocol summary

Summary

The aim of this study is to evaluate the efficacy of allopurinol in preventing contrast induced nephropathy. Inclusion criteria is admission for elective PCI and exclusion criteria is serum creatinin>3mg/dL or eGFR<60ml/min; sever hepatic failure; concomitant use of 6mercaptapurin or azathioprine or warfarin. The study population is all patients admitted for elective PCI in Tehran Heart Center and the sample size is 200. 24 hours before PCI, blood samples are drawn to measure serum creatinin, uric acid, and serum cystatin C. After that patients are grouped in two groups-placebo and intervention. Patients in the intervention group receive two doses of 600mg allopurinol, one 24 hours and one immediately before the procedure. The control group will receive the placebo at these times. 24 hours after the procedure, another blood sample will be drawn to measure serum creatinin, uric acid, and serum cystatin C. The rate of contrast induced nephropathy will be compared between the two groups using aforementioned biomarkers. Also, adverse drug reactions will be recorded.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2015120525372N1**

Registration date: **2017-06-06, 1396/03/16**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2017-06-06, 1396/03/16

Registrant information

Name

Zahra Alimohammad Ghelichkhan

Name of organization / entity

Urmia University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 8840 0871

Email address

z-ghelichkhan@razi.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Tehran University of Medical Sciences

Expected recruitment start date

2012-10-13, 1391/07/22

Expected recruitment end date

2014-09-01, 1393/06/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of allopurinol in preventing contrast induced nephropathy among patients undergoing elective PCI

Public title

Effect of allopurinol in preventing kidney damage due to coronary angiography

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria: All patients undergoing elective PCI
Exclusion criteria: Patients who are candidates for CABG or primary PCI; Patients with gout or prior use of allopurinol; Serum creatinin >3mg/dL or eGFR<60ml/min; Advanced hepatic failure; Patients who are using azathioprine, 6MP, or warfarin; Patients who

have not filled/signed consent form, or the ones who had shown adverse reaction to the drug in prior use

Age

From **18 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **200**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Tehran University of Medical Sciences

Street address

Tehran University of Medical Sciences

City

Tehran

Postal code

Approval date

2015-05-23, 1394/03/02

Ethics committee reference number

149384-28024-159-01-94

Health conditions studied

1

Description of health condition studied

contrast induced nephropathy

ICD-10 code

Y57.5

ICD-10 code description

X-ray contrast media

Primary outcomes

1

Description

serum cystatin C

Timepoint

24 hours after PCI

Method of measurement

blood sample

2

Description

serum creatinin

Timepoint

24 hours after PCI

Method of measurement

blood sample

Secondary outcomes

1

Description

serum uric acid

Timepoint

24 hours before and after PCI

Method of measurement

blood sample

Intervention groups

1

Description

allopurinol, 600 mg PO, 24 hours before PCI

Category

Treatment - Drugs

2

Description

placebo, 24 hours before PCI

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Tehran Heart Center

Full name of responsible person

Zahra Alimohammad Ghelich Khan

Street address

Clinical Pharmacy Dept., School of Pharmacy, Tehran University of Medical Sciences

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Dr. Masoud Yunesian

Street address

North Kargar-Ave

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran Heart Center

Full name of responsible person

Azita Hajhossein Talasaz

Position

Clinical Pharmacist

Other areas of specialty/work

Street address

Tehran, Tehran Heart Center

City

Tehran

Postal code

Phone

+98 21 8802 9610

Fax

Email

ahhtalasaz@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Azita Hajhossein Talasaz

Position

PhD

Other areas of specialty/work

Street address

clinical pharmacy department,school of pharmacy,Tehran university of medical sciences

City

tehran

Postal code

Phone

+98 21 8802 9256

Fax

Email

ahhtalasaz@yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Full name of responsible person

Zahra Alimohammad Ghelich Khan

Position

Other areas of specialty/work

Street address

City

Postal code

Phone

+98 21 8840 0871

Fax

Email

z.gkhan@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty